argenx SE
argenx SE Q2 FY26 Results — Earnings Call Analysis
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q2 FY26 call signalled
3 of 3 strong
The short version
- Continued strong momentum and growth expected for VYVGART across MG and CIDP indications, with new patient demand among the highest ever in Q1 2026. - Operating profit for Q1 2026 was $394 million with a 30% operating margin, representing 183% year-over-year growth.
From argenx SE's Q2 FY26 earnings-call transcript · updated 29 May 2026.
Revenue & Sales Performance
- Continued strong momentum and growth expected for VYVGART across MG and CIDP indications, with new patient demand among the highest ever in Q1 2026.
- Expansion into broader MG populations including seronegative, ocular, and pediatric segments anticipated to drive growth.
- Significant opportunity ahead as nearly 80% of MG patients are not yet on biologics.
- Growth catalyzed by early-line adoption; 4 out of 5 healthcare providers prefer VYVGART as the first biologic in generalized MG.
- Pipeline advancements including empasiprubart for MMN and potential launches in autoimmune myositis and Sjogren’s expected to contribute medium-term growth.
2 more points from argenx SE's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what argenx SE said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Increased R&D expenses driven by CMC investments to support expected launch of VYVGART subcutaneous auto-injector in 2027.
- Continued development of efgartigimod across several indications and advancing pipeline assets.
- Strategic investments focused on delivering long-term growth through innovation and transformational outcomes for patients.
- Strong cash position ($4.9 billion) enables significant flexibility to deploy capital for:
- Maximizing VYVGART commercial opportunity,
- Advancing pipeline,
- Strengthening supply chain,
- Pursuing business development to source novel biology for long-term growth.
2 more points from argenx SE's call on capex
Pro opens every point from 15K+ earnings calls
Fundraising & Capital Structure
See what argenx SE said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from argenx SE's call on order book
Pro opens every point from 15K+ earnings calls
Continue your research
Others in Biotechnology this season
- Arrowhead Pharmaceuticals, Inc. (Q2 FY26)
Arrowhead Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. REDEMPLO launch momentum continues strong with prescriptions accelerating nearly threefold o
- Madrigal Pharmaceuticals, Inc. (Q2 FY26)
Madrigal Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. The company expects steady patient additions and robust net sales growth through 2026, with Q
- Exelixis, Inc. (Q2 FY26)
Exelixis, Inc. Q2 FY26 quarterly results analysis. CABOMETYX revenue and demand continue strong growth; Q1 2026 U.S. Market Cap $12,932, P/E 16.5. AI-powered ea
- Ionis Pharmaceuticals, Inc. (Q2 FY26)
Ionis Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. DAWNZERA sales expected at $110M-$120M in 2026, driven by switches from existing prophylactics a
Arthneeti Pro · Annual
argenx SE and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were argenx SE Q2 FY26 results?
- Continued strong momentum and growth expected for VYVGART across MG and CIDP indications, with new patient demand among the highest ever in Q1 2026. - Operating profit for Q1 2026 was $394 million with a 30% operating margin, representing 183% year-over-year growth.
What is argenx SE share price analysis?
argenx SE currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 36.0 with a market cap of $52,039. Investors should review the full earnings analysis for detailed insights.
Is argenx SE planning capital expenditure?
- Increased R&D expenses driven by CMC investments to support expected launch of VYVGART subcutaneous auto-injector in 2027.
Keep argenx SE on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.